SG11201809802PA - Compositions for treating or preventing vasomotor symptoms - Google Patents
Compositions for treating or preventing vasomotor symptomsInfo
- Publication number
- SG11201809802PA SG11201809802PA SG11201809802PA SG11201809802PA SG11201809802PA SG 11201809802P A SG11201809802P A SG 11201809802PA SG 11201809802P A SG11201809802P A SG 11201809802PA SG 11201809802P A SG11201809802P A SG 11201809802PA SG 11201809802P A SG11201809802P A SG 11201809802PA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- compositions
- osaka
- treating
- pct
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Vascular Medicine (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662349179P | 2016-06-13 | 2016-06-13 | |
| PCT/JP2017/021569 WO2017217351A1 (en) | 2016-06-13 | 2017-06-12 | Compositions for treating or preventing vasomotor symptoms |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201809802PA true SG11201809802PA (en) | 2018-12-28 |
Family
ID=59101629
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201809802PA SG11201809802PA (en) | 2016-06-13 | 2017-06-12 | Compositions for treating or preventing vasomotor symptoms |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US10993939B2 (zh) |
| EP (2) | EP4140484A1 (zh) |
| JP (1) | JP6943887B2 (zh) |
| KR (2) | KR20230005413A (zh) |
| CN (4) | CN114748624A (zh) |
| AU (2) | AU2017285609B2 (zh) |
| BR (1) | BR112018075403A2 (zh) |
| CA (1) | CA3022808A1 (zh) |
| CO (1) | CO2018013692A2 (zh) |
| ES (1) | ES2957232T3 (zh) |
| IL (1) | IL262664B (zh) |
| MX (1) | MX2018015399A (zh) |
| PH (1) | PH12018502618A1 (zh) |
| RU (1) | RU2768875C2 (zh) |
| SG (1) | SG11201809802PA (zh) |
| TW (1) | TWI739850B (zh) |
| WO (1) | WO2017217351A1 (zh) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3727383A1 (en) | 2017-12-19 | 2020-10-28 | Mitsubishi Tanabe Pharma Corporation | Compositions and methods for treating or preventing vasomotor symptoms |
| CN113677334B (zh) * | 2019-02-01 | 2024-04-09 | 马歇尔大学科研协会 | 瞬时受体电位melastatin 8(trpm8)拮抗剂和相关方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006122156A2 (en) * | 2005-05-09 | 2006-11-16 | Hydra Biosciences, Inc. | Compounds for modulating trpv3 function |
| WO2009073788A1 (en) | 2007-12-07 | 2009-06-11 | Firestone Leigh H | Compositions and methods for treating menopausal females |
| CA2747637A1 (en) | 2008-12-18 | 2010-07-15 | Janssen Pharmaceutica Nv | Sulfamides as trpm8 modulators |
| WO2010103381A1 (en) | 2009-03-13 | 2010-09-16 | Glenmark Pharmaceuticals S.A. | Spirocyclic piperidine derivatives as trpm 8 modulators |
| EP2424517A4 (en) | 2009-05-01 | 2013-01-23 | Raqualia Pharma Inc | SULFAMOYLBENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS |
| TW201103941A (en) | 2009-06-10 | 2011-02-01 | Janssen Pharmaceutica Nv | Benzimidazole derivatives useful as TRPM8 channel modulators |
| EP2481727A1 (en) | 2011-01-28 | 2012-08-01 | Dompe S.p.A. | TRPM8 receptor antagonists |
| PL2686302T3 (pl) * | 2011-03-16 | 2017-01-31 | Mitsubishi Tanabe Pharma Corporation | Związki sulfonamidowe mające działanie antagonistyczne dla TRPMS |
| JP2014527511A (ja) | 2011-06-24 | 2014-10-16 | アムジエン・インコーポレーテツド | Ｔｒｐｍ８拮抗剤及び治療におけるそれらの使用 |
| DK2793883T3 (en) | 2011-12-19 | 2018-07-30 | Dompe Farm Spa | TRPM8 antagonists |
| WO2014042238A1 (ja) * | 2012-09-14 | 2014-03-20 | 田辺三菱製薬株式会社 | スルホンアミド化合物 |
| JP5985453B2 (ja) * | 2012-09-14 | 2016-09-06 | 田辺三菱製薬株式会社 | 医薬組成物 |
| JP6352413B2 (ja) * | 2013-10-22 | 2018-07-04 | エドワード タク ウェイＷＥＩ， Ｅｄｗａｒｄ Ｔａｋ | 感覚的不快感の治療向け局所薬としてのジ−イソプロピル−アルカン（ｄａｐａ）化合物 |
-
2017
- 2017-06-12 US US16/308,932 patent/US10993939B2/en active Active
- 2017-06-12 AU AU2017285609A patent/AU2017285609B2/en active Active
- 2017-06-12 TW TW106119449A patent/TWI739850B/zh active
- 2017-06-12 RU RU2019100424A patent/RU2768875C2/ru active
- 2017-06-12 EP EP22194364.0A patent/EP4140484A1/en not_active Withdrawn
- 2017-06-12 ES ES17732243T patent/ES2957232T3/es active Active
- 2017-06-12 SG SG11201809802PA patent/SG11201809802PA/en unknown
- 2017-06-12 WO PCT/JP2017/021569 patent/WO2017217351A1/en active Application Filing
- 2017-06-12 EP EP17732243.5A patent/EP3468557B1/en active Active
- 2017-06-12 CN CN202210390477.XA patent/CN114748624A/zh active Pending
- 2017-06-12 JP JP2018564985A patent/JP6943887B2/ja active Active
- 2017-06-12 KR KR1020227044605A patent/KR20230005413A/ko not_active Application Discontinuation
- 2017-06-12 MX MX2018015399A patent/MX2018015399A/es unknown
- 2017-06-12 CN CN202110496161.4A patent/CN113384577A/zh active Pending
- 2017-06-12 CN CN202110496162.9A patent/CN113398124A/zh active Pending
- 2017-06-12 BR BR112018075403-0A patent/BR112018075403A2/pt not_active Application Discontinuation
- 2017-06-12 CA CA3022808A patent/CA3022808A1/en active Pending
- 2017-06-12 KR KR1020187036433A patent/KR20190017800A/ko not_active IP Right Cessation
- 2017-06-12 CN CN201780036529.0A patent/CN109310689A/zh active Pending
-
2018
- 2018-10-29 IL IL262664A patent/IL262664B/en unknown
- 2018-12-12 PH PH12018502618A patent/PH12018502618A1/en unknown
- 2018-12-18 CO CONC2018/0013692A patent/CO2018013692A2/es unknown
-
2021
- 2021-02-27 US US17/187,769 patent/US20210177830A1/en active Pending
-
2022
- 2022-08-04 AU AU2022211877A patent/AU2022211877A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3468557A1 (en) | 2019-04-17 |
| WO2017217351A1 (en) | 2017-12-21 |
| AU2017285609B2 (en) | 2022-08-18 |
| IL262664B (en) | 2021-10-31 |
| CA3022808A1 (en) | 2017-12-21 |
| ES2957232T3 (es) | 2024-01-15 |
| PH12018502618A1 (en) | 2019-10-07 |
| CN113384577A (zh) | 2021-09-14 |
| CN113398124A (zh) | 2021-09-17 |
| MX2018015399A (es) | 2019-04-29 |
| CO2018013692A2 (es) | 2019-01-18 |
| JP6943887B2 (ja) | 2021-10-06 |
| IL262664A (en) | 2018-12-31 |
| TWI739850B (zh) | 2021-09-21 |
| EP3468557B1 (en) | 2023-07-26 |
| US20210177830A1 (en) | 2021-06-17 |
| BR112018075403A2 (pt) | 2019-03-19 |
| KR20190017800A (ko) | 2019-02-20 |
| US10993939B2 (en) | 2021-05-04 |
| AU2022211877A1 (en) | 2022-09-01 |
| RU2019100424A (ru) | 2020-07-15 |
| US20190142821A1 (en) | 2019-05-16 |
| JP2019517573A (ja) | 2019-06-24 |
| RU2768875C2 (ru) | 2022-03-25 |
| EP4140484A1 (en) | 2023-03-01 |
| RU2019100424A3 (zh) | 2020-09-24 |
| KR20230005413A (ko) | 2023-01-09 |
| AU2017285609A1 (en) | 2019-01-03 |
| TW201803595A (zh) | 2018-02-01 |
| CN114748624A (zh) | 2022-07-15 |
| CN109310689A (zh) | 2019-02-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201909949XA (en) | Targeted immunotolerance | |
| SG11201811470PA (en) | Pyrazolopyrimidine derivatives as kinase inhibitor | |
| SG11201808566WA (en) | Polymorphic form of n-{6-(2-hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2h-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide | |
| SG11201909325RA (en) | 2-amino-quinoline derivatives | |
| SG11201804758QA (en) | Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab | |
| SG11201906891RA (en) | Methods for the administration of certain vmat2 inhibitors | |
| SG11201906386XA (en) | Combination therapy involving diaryl macrocyclic compounds | |
| SG11201810280YA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201806583XA (en) | Compositions containing tucaresol or its analogs | |
| SG11201907023UA (en) | Method of reducing neutropenia | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201901558VA (en) | Pth compounds with low peak-to-trough ratios | |
| SG11201809751XA (en) | Egfr inhibitor compounds | |
| SG11201408237YA (en) | Compound as wnt signaling inhibitor, composition, and use thereof | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201408750VA (en) | NOVEL FUSED PYRIDINE DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS | |
| SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900633XA (en) | Piperidine cxcr7 receptor modulators | |
| SG11201805001UA (en) | Method of treating influenza a | |
| SG11201808686VA (en) | Synthesis of indazoles | |
| SG11201902949PA (en) | Pharmaceutical compositions and methods of treating cardiovascular diseases | |
| SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
| SG11201805149XA (en) | Compositions comprising 15-hepe and methods of using the same | |
| SG11201900214UA (en) | Iso-citrate dehydrogenase (idh) inhibitor |